Path: /organizations/treventis-corporation
Type: Biotechnology Company
Headquarters: Toronto, Ontario, Canada
Founded: 2005
Treventis Corporation is a Canadian biotechnology company headquartered in Toronto, Ontario, dedicated to developing disease-modifying treatments for Alzheimer's disease and related tauopathies. The company's focus on tau aggregation inhibition represents a promising approach to addressing the neurofibrillary degeneration that correlates with cognitive decline in Alzheimer's disease.
Tau is a microtubule-associated protein that stabilizes neuronal cytoskeleton. In Alzheimer's disease and related 4R-tauopathies, tau becomes hyperphosphorylated, misfolds, and aggregates into neurofibrillary tangles—a hallmark lesion that correlates strongly with neuronal loss and cognitive impairment.
Treventis develops small molecule inhibitors that prevent the pathological aggregation of tau protein. This approach differs from antibody-based strategies that target extracellular tau or attempt to clear already-formed tangles. By inhibiting aggregation, Treventis aims to:
Treventis employs structure-based drug design to identify compounds that bind to specific regions of tau and prevent its pathological aggregation. The company uses:
Key targets for tau aggregation inhibitors include:
| Program | Target | Stage | Indication |
|---|---|---|---|
| TRV-001 | Tau aggregation | Preclinical | Alzheimer's Disease |
| TRV-002 | Tau aggregation | Discovery | PSP/CBD |
Treventis collaborates with leading Canadian research institutions:
The company benefits from funding programs through:
Treventis competes with other companies developing tau-targeted approaches: